- ￥800 - 2500
- Sino Biological
- 北京
- 40590-T62
- 2025年09月19日
- WB,ELISA
- Rabbit
- 兔
企业认证
研选同类产品更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 用户评价
- 文献和实验
- 技术资料
- 免疫原：
Recombinant SARS-CoV-2 / 2019-nCoV Spike/S2 Protein (Catalog#40590-V08B)
- 亚型：
Rabbit IgG
- 形态：
液体
- 保存条件：
在-20℃ to -80℃
- 克隆性：
PAb
- 适应物种：
兔
- 保质期：
12个月
- 抗原来源：
40590-V08B
- 目录编号：
40590-T62
- 级别：
免疫学试剂
- 库存：
99
- 供应商：
北京义翘神州科技股份有限公司
- 宿主：
Rabbit
- 应用范围：
WB,ELISA
- 浓度：
WB: 1:1000-1:5000;ELISA: 1:5000-1:10000
- 靶点：
Spike
- 抗体英文名：
SARS-CoV-2 (2019-nCoV) Spike S2 Antibody, Rabbit PAb, Antigen Affinity Purified
- 抗体名：
新冠病毒 Spike S2 兔多抗
- 规格：
20 µL/100 µL
| 规格： | 20 µL | 产品价格： | ￥800.0 |
|---|---|---|---|
| 规格： | 100 µL | 产品价格： | ￥2500.0 |
Coronavirus spike|Coronavirus spike antibody|Coronavirus spike抗体|Anti-2019-nCoV 兔多抗（产品说明）
抗体种属：2019-nCoV
抗体靶点：Spike
抗体应用：WB,ELISA
抗原货号：40590-V08B
抗原描述：Recombinant SARS-CoV-2 / 2019-nCoV Spike/S2 Protein (Catalog#40590-V08B)
抗体宿主：Rabbit
抗体Ig类型：Rabbit IgG
抗体纯化方法：Protein A & Antigen Affinity
抗体制备：Produced in rabbits immunized with recombinant SARS-CoV-2 / 2019-nCoV Spike/S2 Protein (Catalog#40590-V08B; YP_009724390.1; Ser686-Pro1213). The specific IgG was purified by SARS-CoV-2 / 2019-nCoV Spike/S2 affinity chromatography.
抗体特异性：SARS-CoV-2 (2019-nCoV) Spike S2 (ECD, His tag) (Cat# 40590-V08B)
抗体保存：This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
用户评价
暂无用户评价
文献和实验1, Takeda Y, et al. Saxifraga spinulosa-Derived Components Rapidly Inactivate Multiple Viruses Including SARS-CoV-2.Viruses, PubMed ID: 32605306
2, Deinhardt-Emmer S, et al. SARS-CoV-2 causes severe epithelial inflammation and barrier dysfunction.Journal of virology, PubMed ID: 33637603
3, Dispinseri S, et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival.Nature communications, PubMed ID: 33976165
4, Wang Q, et al. iScience, PubMed ID: 34746689
5, Kim GN, et al. A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2.PLoS pathogens, PubMed ID: 34914812
6, Yu S, et al. SARS-CoV-2 spike engagement of ACE2 primes S2' site cleavage and fusion initiation.Proceedings of the National Academy of Sciences of the United States of America, PubMed ID: 34930824
7, Lubinski B, et al. Functional evaluation of the P681H mutation on the proteolytic activation of the SARS-CoV-2 variant B.1.1.7 (Alpha) spike.iScience, PubMed ID: 34909610
8, Shuai H, et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron.Nature, PubMed ID: 35062016
9, Du S, et al. The "LLQY" motif on SARS-CoV-2 spike protein affects S incorporation into virus particles.Journal of virology, PubMed ID: 35045269
10, Frolova EI, et al. Acquisition of Furin Cleavage Site and Further SARS-CoV-2 Evolution Change the Mechanisms of Viral Entry, Infection Spread, and Cell Signaling.Journal of virology, PubMed ID: 35876526
11, Chan JF, et al. Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2.Cell Reports Medicine, PubMed ID: 36084644
12, Qu P, et al. Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants.mBio, PubMed ID: 36625591
13, Frolov I, et al. All Domains of SARS-CoV-2 nsp1 Determine Translational Shutoff and Cytotoxicity of the Protein.Journal of virology, PubMed ID: 36847528
14, Qu P, et al. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants.Cell reports, PubMed ID: 37104089
15, Xu D, et al. PLSCR1 is a cell-autonomous defence factor against SARS-CoV-2 infection.Nature, PubMed ID: 37438530
16, Shuai H, et al. The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5.EBioMedicine, PubMed ID: 37579626
17, Liu L, et al. Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking.Immunity, PubMed ID: 37776849
18, Greene KS, et al. Inhibiting Glutamine Metabolism Blocks Coronavirus Replication in Mammalian Cells.bioRxiv : the preprint server for biology, PubMed ID: 37808692
19, Häring C, et al. The Local Anaesthetic Procaine Prodrugs ProcCluster® and Procaine Hydrochloride Impair SARS-CoV-2 Replication and Egress In Vitro.International journal of molecular sciences, PubMed ID: 37834031
20, Hu B, et al. Divergent trajectory of replication and intrinsic pathogenicity of SARS-CoV-2 Omicron post-BA.2/5 subvariants in the upper and lower respiratory tract.EBioMedicine, PubMed ID: 38101297
21, Fan J, et al. Early Emerging SARS-CoV-2 Spike Mutants Are Diversified in Virologic Properties but Elicit Compromised Antibody Responses.Viruses, PubMed ID: 38140642
22, Qu P, et al. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants.Cell, PubMed ID: 38194968
23, Pérez-Vargas J, et al. Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals.Antiviral research, PubMed ID: 38548023
24, Su W, et al. Furin Egress from the TGN is Regulated by Membrane-Associated RING-CH Finger (MARCHF) Proteins and Ubiquitin-Specific Protease 32 (USP32) via Nondegradable K33-Polyubiquitination.Advanced science (Weinheim, Baden-Wurttemberg, Germany), PubMed ID: 39031635
技术资料暂无技术资料 索取技术资料
